HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berkowitz, B. A. Articles by Sachs, G. Search for Related Content PubMed PubMed Citation Articles by Berkowitz, B. A. Articles by Sachs, G.

Life Cycle of A Block Buster Drug

Discovery and Development of Omeprazole (Prilosec^TM)

ABSTRACT

Blockbuster drugs share a variety of common features, among which is the tendency to create entirely new markets. For example, an early "informed" estimate of the potential market size for the hypothetically "perfect" peptic ulcer drug was thirty-five million dollars. Based on current sales, however, we reckon this hypothesis to have underestimated the actual market demand for omeprazole (Prilosec^TM) by about 400-fold. Similarly, prior to the introduction of the "retired" blockbusters chlordiazepoxide and diazepam (Librium^TM and Valium^TM), the market for "minor tranquilizers" in the treatment of anxiety and neurosis did not exist. Thus, once an emerging blockbuster seems to be therapeutically working, it is not unusual for diagnostic rates of the disease for which it is indicated and efficacious to actually increase. Top blockbuster drugs generally have or appear to have a high margin of safety.

This article has been cited by other articles:

				J. S. Lazo Rear-view Mirrors and Crystal Balls: A Brief Reflection on Drug Discovery Mol. Interv., April 1, 2008; 8(2): 60 - 63. [Full Text] [PDF]